Why the study?
Does active smoking increase plasma levels of soluble CD40 ligand in patients with acute myocardial infarction?
Does active smoking increase plasma levels of soluble CD40 ligand in patients with acute myocardial infarction?
Smokers with acute myocardial infarction exhibit higher circulating levels of soluble CD40 ligand, suggesting an increased prothrombotic state that may warrant optimal antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
May signal heightened thrombotic risk in smokers with acute MI; leaves open causality and need for prospective antiplatelet trials.
Coronary artery disease (CAD) is believed to be the single leading cause of death in both men and women in the world. Smoking is the most important risk factor for CAD. Smoking increases platelet aggregation and thrombus formation. CD40 ligand (CD40L) is a transmembrane glycoprotein derived from activated platelets. It participates in thrombus formation during the acute phase of acute myocardial infarction (MI). Elevation of CD40L identifies the patients who are at highest risk for cardiac events and who are likely to benefit from treatment with the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists. The purpose of this study was to evaluate levels of CD40L in smokers with acute MI. Fifty-seven patients with acute MI were enrolled in this study. Thirty-one smokers were compared with 26 non-smokers. Soluble CD40L level in the plasma was determined by a standard enzyme-linked immunosorbent assay. Circulating levels of CD40L were higher in the smokers' group. Smokers with acute MI may have increased risk for thrombotic complications during acute MI, and optimal antiaggregant therapy should be administered.
No takes yet. Share an insight, caveat, or question.
Kayrak et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: